Autolus Therapeutics (NASDAQ: AUTL) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Autolus Therapeutics to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.
Earnings & Valuation
This table compares Autolus Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Autolus Therapeutics||$1.41 million||-$44.75 million||-19.72|
|Autolus Therapeutics Competitors||$897.63 million||$190.37 million||-1.33|
Autolus Therapeutics’ peers have higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
40.6% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current recommendations for Autolus Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Autolus Therapeutics Competitors||834||2774||6059||261||2.58|
Autolus Therapeutics presently has a consensus price target of $44.00, suggesting a potential upside of 57.14%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.52%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than its peers.
This table compares Autolus Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Autolus Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
About Autolus Therapeutics
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.